Abbvie Inc (ABBV)

$253.38 -1.11 (-0.44%)
Market Cap 449.63B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 24.96
Forward PE 17.97
Profit Margin 6.91%
Debt to Equity Ratio -11.02
Volume 4,332,695
Avg Vol 7,138,552
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 64%
Beta 0.30
Analysts Strong Sell
Price Target $264.62

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
DidYouReadThis
DidYouReadThis Jul. 20 at 9:00 PM
$OTLK $ABBV If there was one day an approved alternative to repeat eye injections, that was maybe a one and done that was potentially estimated at 200k+ total for both eyes, but no treatment ever needed again, 1. What percent of people do you think might go for that? 2. What % do you think insurance might potentially cover? 3. What decade do you think gene therapy overall for all pharma might become more common?
1 · Reply
GoforProMIS
GoforProMIS Jul. 20 at 8:41 PM
$PMN exactly and more precise: Big buys shows accumulation Medium and Small selling anyway the path is clear with Alzheimer Disease, Parkinson, Schizophrenia, ALS and several other diseases with PMN310 platform medicine the biding war for big pharmaceutical companies like $BMY $JNJ $ABBV is only in beginning the main target is AD competition Eli Lilly, Biogen, Eisai and Roche-Novartis. So everyone should know what’s happening 🔜 📈
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 20 at 7:44 PM
$SLS 31.6 Days Per Event from the 60th Event on Dec 8th 2024 to the 72nd Dec 26th 2025. 22 Days Per Event from the 72nd to the 78th - on May 11. it has now Been 70 Days ... One thing I've been intrigued by, 3 Partners in the Launch of the SLS Rocket -- feels like $ABBV buys 009 $MRK and $BMY Take GPS. BE HOLDING.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 20 at 7:36 PM
$SLS BAT Since 2018 -- https://www.fda.gov/drugs/fda-approves-venetoclax-combination-aml-adults - It is Now DAY 70... No Real Holders are letting any shares go, now this close to the 80th Event PR Incoming THIS Week and the following Phase 3 Results, that are worth 27x the current Share price. ​$20 - $25 THIS WEEK on the 80th Event PR and climbing 10x+ $135 per share on the P3 Results. Mark this Post. Gps is about to get a Fda green light to Generate Tens of Billions in Real Revenue - worth every nickel of $40B to $PFE $LLY $ABBV DAY 70 ...
0 · Reply
GoforProMIS
GoforProMIS Jul. 20 at 5:02 PM
$PMN looks nice today with +10% . It seems big Pharma knows something about the results of PMN310 Alzheimer disease and the platform for several other diseases like Parkinson, ALS, Schizophrenia etc. https://www.promisneurosciences.com/news-media/press-releases/detail/269/promis-neurosciences-reports-first-human-evidence-of $ABBV $AMRX $RHHBY $TEVA
0 · Reply
GoforProMIS
GoforProMIS Jul. 20 at 4:51 PM
$PMN shows up today with +10% It seems big Pharma knows something about the results of PMN310 Alzheimer disease and the platform for several other diseases like Parkinson, ALS, Schizophrenia etc. https://www.promisneurosciences.com/news-media/press-releases/detail/269/promis-neurosciences-reports-first-human-evidence-of $ABBV $AMRX $NVS$TEVA
0 · Reply
DidYouReadThis
DidYouReadThis Jul. 20 at 2:47 PM
$RGNX New here. 1. For the #DD people-is there a source you know of with an estimated range for treatment for wet AMD, retina, DME etc. estimated cost per treatment per eye 2. When is the trial end date for eyes? 3. Does anyone know any stocks that were considered gene therapy and how smooth insurance might go for that? 4. Is $ABBV doing some kind of 50/50 thing on multiple/all or only one in development? 5. What are the optimistic and pessimistic targets for percent of the market for wet AMD?
1 · Reply
opt_guru101
opt_guru101 Jul. 20 at 1:27 PM
$ABBV 252 support
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 20 at 11:55 AM
$SLS $LLY $ABBV No Real Holders are letting any shares go, now this close to the 80th Event PR Incoming This week and the Phase 3 Results, that are worth 27x the current Share price. ​$20 - $25 THIS WEEK on the 80th Event PR and climbing 10x+ $135 per share on the P3 Results. Gps is about to get a Fda green light to Generate Tens of Billions in Real Revenue - worth every nickel of $40B to $LLY SABBV PFE.
1 · Reply
GoforProMIS
GoforProMIS Jul. 20 at 11:42 AM
$PMN with ProMIS Neurosciences Platform Strategy and PMN310 it target also: 2. Parkinson's Disease (PD / Parkinson-Krankheit) Pharmaceutical sales 2026: approx. 6.20 to 8.38 billion USD Leading companies (market leaders): $ABBV (market leader in advanced-stage disease with the levodopa/carbidopa intestinal pump Duodopa/Duopa and the newer subcutaneous pump Produodopa) $AMRX Pharmaceuticals (strong market presence via Rytary and newer generic combinations) Supernus Pharmaceuticals (focus on apomorphine injections and films such as Apokyn / Kynmobi) $TEVA Pharmaceutical Industries (established presence with the classic drug Azilect (rasagiline) and generics) $NVS AG & F. Hoffmann-La Roche (strong historical presence as well as active development of new antibodies/pipeline candidates)
0 · Reply
Latest News on ABBV
AbbVie’s Allergan Aesthetics receives approval for Boey in Europe

2026-07-17T12:05:34.000Z - 3 days ago

AbbVie’s Allergan Aesthetics receives approval for Boey in Europe

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

Jul 17, 2026, 8:00 AM EDT - 3 days ago

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

AbbVie price target raised to $260 from $230 at Citi

2026-07-15T10:21:06.000Z - 5 days ago

AbbVie price target raised to $260 from $230 at Citi

SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development

Jul 14, 2026, 8:05 AM EDT - 6 days ago

SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development

Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals

Jul 13, 2026, 5:06 PM EDT - 7 days ago

Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals

APGE SBIO

AbbVie price target raised to $260 from $230 at UBS

2026-07-13T16:30:09.000Z - 7 days ago

AbbVie price target raised to $260 from $230 at UBS

AbbVie price target raised to $300 from $258 at BMO Capital

2026-07-13T12:27:09.000Z - 7 days ago

AbbVie price target raised to $300 from $258 at BMO Capital

2 ‘Strong Buy’ Dividend Aristocrat Stocks to Grab Right Now for August Payouts

2026-07-10T23:36:54.000Z - 9 days ago

2 ‘Strong Buy’ Dividend Aristocrat Stocks to Grab Right Now for August Payouts

ABT

AbbVie price target raised to $280 from $260 at RBC Capital

2026-07-10T13:10:21.000Z - 10 days ago

AbbVie price target raised to $280 from $260 at RBC Capital

AbbVie price target raised to $276 from $234 at BofA

2026-07-10T10:31:16.000Z - 10 days ago

AbbVie price target raised to $276 from $234 at BofA

AbbVie price target raised to $295 from $260 at Wells Fargo

2026-07-10T10:20:22.000Z - 10 days ago

AbbVie price target raised to $295 from $260 at Wells Fargo

AbbVie price target raised to $280 from $260 at JPMorgan

2026-07-09T12:06:14.000Z - 11 days ago

AbbVie price target raised to $280 from $260 at JPMorgan

AbbVie price target raised to $261 from $249 at Guggenheim

2026-07-09T11:30:42.000Z - 11 days ago

AbbVie price target raised to $261 from $249 at Guggenheim

Buy these quality, low-stress stocks for the summer, says Jefferies

Jul 7, 2026, 11:45 AM EDT - 13 days ago

Buy these quality, low-stress stocks for the summer, says Jefferies

AXP HD LOW MCD NFLX PEP PG

AbbVie says Q2 EPS to include unfavorable impact of 17c

2026-07-06T20:20:39.000Z - 14 days ago

AbbVie says Q2 EPS to include unfavorable impact of 17c

AbbVie sees Q2 adjusted EPS ex-items $3.57-$3.61, consensus $3.77

2026-07-06T20:20:19.000Z - 14 days ago

AbbVie sees Q2 adjusted EPS ex-items $3.57-$3.61, consensus $3.77

AbbVie cuts FY26 adjusted EPS view to $13.91-$14.11 from $14.08-$14.28

2026-07-06T20:20:13.000Z - 14 days ago

AbbVie cuts FY26 adjusted EPS view to $13.91-$14.11 from $14.08-$14.28

AbbVie says Tepkinly combo approved by EC for lymphoma treatment

2026-07-06T17:50:14.000Z - 14 days ago

AbbVie says Tepkinly combo approved by EC for lymphoma treatment

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

Jul 6, 2026, 1:45 PM EDT - 14 days ago

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

AbbVie price target raised to $300 from $275 at HSBC

2026-07-06T14:20:07.000Z - 14 days ago

AbbVie price target raised to $300 from $275 at HSBC

AbbVie price target raised to $265 from $240 at Cantor Fitzgerald

2026-07-06T11:05:07.000Z - 14 days ago

AbbVie price target raised to $265 from $240 at Cantor Fitzgerald

House committee opens probe into Merck, AbbVie China drug trials, Reuters says

2026-06-30T14:05:22.000Z - 20 days ago

House committee opens probe into Merck, AbbVie China drug trials, Reuters says

MRK

US House committee opens investigation into Merck, AbbVie China drug trials

Jun 30, 2026, 6:02 AM EDT - 20 days ago

US House committee opens investigation into Merck, AbbVie China drug trials

MRK

AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jun 29, 2026, 4:15 PM EDT - 21 days ago

AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

Jun 29, 2026, 3:10 AM EDT - 21 days ago

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo

Jun 29, 2026, 3:00 AM EDT - 21 days ago

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

Jun 26, 2026, 4:50 PM EDT - 24 days ago

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

Healthcare stocks have become a haven for investors ditching tech

Jun 26, 2026, 2:39 PM EDT - 24 days ago

Healthcare stocks have become a haven for investors ditching tech

ABSI APGE JNJ LLY MRNA SNY XBI

AbbVie to Host Second-Quarter 2026 Earnings Conference Call

Jun 26, 2026, 8:00 AM EDT - 24 days ago

AbbVie to Host Second-Quarter 2026 Earnings Conference Call

AbbVie's $11 Billion Immunology Bet

Jun 24, 2026, 12:51 PM EDT - 26 days ago

AbbVie's $11 Billion Immunology Bet

APGE

BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026

Jun 24, 2026, 8:00 AM EDT - 26 days ago

BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

Jun 23, 2026, 8:00 AM EDT - 27 days ago

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

Jun 23, 2026, 5:00 AM EDT - 27 days ago

AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

Jun 23, 2026, 3:00 AM EDT - 27 days ago

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

EC

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

Jun 22, 2026, 10:30 AM EDT - 4 weeks ago

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

CRDO MU APGE

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

Jun 22, 2026, 10:15 AM EDT - 4 weeks ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE

AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 4 weeks ago

AbbVie Transcript: M&A announcement

AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 4 weeks ago

AbbVie Slides: M&A announcement

AbbVie Press release: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 4 weeks ago

AbbVie Press release: M&A announcement

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

Jun 22, 2026, 7:42 AM EDT - 4 weeks ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

Jun 22, 2026, 7:06 AM EDT - 4 weeks ago

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

APGE

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

Jun 22, 2026, 7:04 AM EDT - 4 weeks ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

Jun 22, 2026, 7:00 AM EDT - 4 weeks ago

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

APGE

AbbVie would gain an experimental eczema drug by buying biotech: report

Jun 20, 2026, 12:11 PM EDT - 4 weeks ago

AbbVie would gain an experimental eczema drug by buying biotech: report

APGE

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

Jun 19, 2026, 11:17 AM EDT - 4 weeks ago

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

APGE

AbbVie Declares Quarterly Dividend

Jun 18, 2026, 4:05 PM EDT - 4 weeks ago

AbbVie Declares Quarterly Dividend

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

Jun 16, 2026, 8:00 AM EDT - 4 weeks ago

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

Jun 12, 2026, 3:00 AM EDT - 5 weeks ago

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

Jun 11, 2026, 7:14 AM EDT - 5 weeks ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ALKS AMGN GILD IBB IHE JNJ KYMR

FDA Issues Complete Response Letter for AbbVie's Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

Jun 10, 2026, 11:47 AM EDT - 5 weeks ago

FDA Issues Complete Response Letter for AbbVie's Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

AbbVie Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 10:40 AM EDT - 5 weeks ago

AbbVie Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

Jun 8, 2026, 8:00 AM EDT - 6 weeks ago

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy

Jun 3, 2026, 7:04 PM EDT - 6 weeks ago

British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

Jun 3, 2026, 3:30 AM EDT - 6 weeks ago

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

BIIB LLY ROP

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Jun 2, 2026, 8:00 AM EDT - 6 weeks ago

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

May 29, 2026, 8:00 AM EDT - 7 weeks ago

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

May 27, 2026, 6:18 PM EDT - 7 weeks ago

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

US FDA approves AbbVie's rare blood cancer drug

May 27, 2026, 3:33 PM EDT - 7 weeks ago

US FDA approves AbbVie's rare blood cancer drug

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

May 22, 2026, 8:00 AM EDT - 2 months ago

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

May 21, 2026, 6:46 PM EDT - 2 months ago

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

May 21, 2026, 4:10 PM EDT - 2 months ago

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 2:20 PM EDT - 2 months ago

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

AbbVie Transcript: AGM 2026

May 8, 2026, 10:00 AM EDT - 2 months ago

AbbVie Transcript: AGM 2026

AbbVie to Present at the Bank of America Securities Healthcare Conference

May 6, 2026, 8:00 AM EDT - 2 months ago

AbbVie to Present at the Bank of America Securities Healthcare Conference

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

May 5, 2026, 8:05 AM EDT - 2 months ago

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

IBD

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

May 1, 2026, 3:05 PM EDT - 2 months ago

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

Big Pharma M&A set for mega year as patent expiries drive deal urgency

May 1, 2026, 10:03 AM EDT - 2 months ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

BMY GILD GSK LLY

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

Apr 30, 2026, 3:00 PM EDT - 2 months ago

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

Apr 30, 2026, 9:00 AM EDT - 2 months ago

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Earnings Call Transcript: Q1 2026

AbbVie Earnings release: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Earnings release: Q1 2026

AbbVie Quarterly report: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Quarterly report: Q1 2026

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 8:32 AM EDT - 2 months ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

Apr 29, 2026, 7:50 AM EDT - 2 months ago

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

AbbVie Reports First-Quarter 2026 Financial Results

Apr 29, 2026, 7:47 AM EDT - 2 months ago

AbbVie Reports First-Quarter 2026 Financial Results

DidYouReadThis
DidYouReadThis Jul. 20 at 9:00 PM
$OTLK $ABBV If there was one day an approved alternative to repeat eye injections, that was maybe a one and done that was potentially estimated at 200k+ total for both eyes, but no treatment ever needed again, 1. What percent of people do you think might go for that? 2. What % do you think insurance might potentially cover? 3. What decade do you think gene therapy overall for all pharma might become more common?
1 · Reply
GoforProMIS
GoforProMIS Jul. 20 at 8:41 PM
$PMN exactly and more precise: Big buys shows accumulation Medium and Small selling anyway the path is clear with Alzheimer Disease, Parkinson, Schizophrenia, ALS and several other diseases with PMN310 platform medicine the biding war for big pharmaceutical companies like $BMY $JNJ $ABBV is only in beginning the main target is AD competition Eli Lilly, Biogen, Eisai and Roche-Novartis. So everyone should know what’s happening 🔜 📈
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 20 at 7:44 PM
$SLS 31.6 Days Per Event from the 60th Event on Dec 8th 2024 to the 72nd Dec 26th 2025. 22 Days Per Event from the 72nd to the 78th - on May 11. it has now Been 70 Days ... One thing I've been intrigued by, 3 Partners in the Launch of the SLS Rocket -- feels like $ABBV buys 009 $MRK and $BMY Take GPS. BE HOLDING.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 20 at 7:36 PM
$SLS BAT Since 2018 -- https://www.fda.gov/drugs/fda-approves-venetoclax-combination-aml-adults - It is Now DAY 70... No Real Holders are letting any shares go, now this close to the 80th Event PR Incoming THIS Week and the following Phase 3 Results, that are worth 27x the current Share price. ​$20 - $25 THIS WEEK on the 80th Event PR and climbing 10x+ $135 per share on the P3 Results. Mark this Post. Gps is about to get a Fda green light to Generate Tens of Billions in Real Revenue - worth every nickel of $40B to $PFE $LLY $ABBV DAY 70 ...
0 · Reply
GoforProMIS
GoforProMIS Jul. 20 at 5:02 PM
$PMN looks nice today with +10% . It seems big Pharma knows something about the results of PMN310 Alzheimer disease and the platform for several other diseases like Parkinson, ALS, Schizophrenia etc. https://www.promisneurosciences.com/news-media/press-releases/detail/269/promis-neurosciences-reports-first-human-evidence-of $ABBV $AMRX $RHHBY $TEVA
0 · Reply
GoforProMIS
GoforProMIS Jul. 20 at 4:51 PM
$PMN shows up today with +10% It seems big Pharma knows something about the results of PMN310 Alzheimer disease and the platform for several other diseases like Parkinson, ALS, Schizophrenia etc. https://www.promisneurosciences.com/news-media/press-releases/detail/269/promis-neurosciences-reports-first-human-evidence-of $ABBV $AMRX $NVS$TEVA
0 · Reply
DidYouReadThis
DidYouReadThis Jul. 20 at 2:47 PM
$RGNX New here. 1. For the #DD people-is there a source you know of with an estimated range for treatment for wet AMD, retina, DME etc. estimated cost per treatment per eye 2. When is the trial end date for eyes? 3. Does anyone know any stocks that were considered gene therapy and how smooth insurance might go for that? 4. Is $ABBV doing some kind of 50/50 thing on multiple/all or only one in development? 5. What are the optimistic and pessimistic targets for percent of the market for wet AMD?
1 · Reply
opt_guru101
opt_guru101 Jul. 20 at 1:27 PM
$ABBV 252 support
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 20 at 11:55 AM
$SLS $LLY $ABBV No Real Holders are letting any shares go, now this close to the 80th Event PR Incoming This week and the Phase 3 Results, that are worth 27x the current Share price. ​$20 - $25 THIS WEEK on the 80th Event PR and climbing 10x+ $135 per share on the P3 Results. Gps is about to get a Fda green light to Generate Tens of Billions in Real Revenue - worth every nickel of $40B to $LLY SABBV PFE.
1 · Reply
GoforProMIS
GoforProMIS Jul. 20 at 11:42 AM
$PMN with ProMIS Neurosciences Platform Strategy and PMN310 it target also: 2. Parkinson's Disease (PD / Parkinson-Krankheit) Pharmaceutical sales 2026: approx. 6.20 to 8.38 billion USD Leading companies (market leaders): $ABBV (market leader in advanced-stage disease with the levodopa/carbidopa intestinal pump Duodopa/Duopa and the newer subcutaneous pump Produodopa) $AMRX Pharmaceuticals (strong market presence via Rytary and newer generic combinations) Supernus Pharmaceuticals (focus on apomorphine injections and films such as Apokyn / Kynmobi) $TEVA Pharmaceutical Industries (established presence with the classic drug Azilect (rasagiline) and generics) $NVS AG & F. Hoffmann-La Roche (strong historical presence as well as active development of new antibodies/pipeline candidates)
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 20 at 8:08 AM
$SLS $LLY $ABBV No Real Holders are letting any shares go, now this close to the 80th Event PR Incoming This week and the Phase 3 Results, that are worth 27x the current Share price.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 20 at 6:17 AM
$SLS $LLY $ABBV Day 70. When the PR hits its too late. Be Holding.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 19 at 9:58 PM
$SLS $20 - $25 THIS WEEK on the 80th Event PR and climbing 10x+ $135 per share on the P3 Results. Gps is about to get a Fda green light to Generate Tens of Billions in Real Revenue - worth every nickel of $40B to $LLY $ABBV PFE . * its Now Day 69 Since the 78th Event -- and we've been seeing an Event Every 22 Days --- The Ceo Told Us ... The Ceo Stated in June he would not be speaking until the 80th Event, and he just said Thursday Night said that he will be SPEAKING NEXT WEEK ... B Holding. ABVX is a Great Example of the Value associated with positive Phase 3 Registrational Results - ie trial results confirming approval and VALUE. Something very Similar will be Happening here, beginning this Week.
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jul. 19 at 4:03 PM
$SLS $MRK $ABBV $JNJ $PFE Part 3. I wouldn’t be surprised one ☝️ Bit if patent expiring in the tune of $380 Billion big pharmaceuticals make a move before Dr. Angelos Stergiou appearance at Fox and Friends. Once GPS CURATIVE news is televised on US # 1 News Network Show it will be hard to contain the SLS KRAKEN. Trading will be halted before any BO PR! ✌️🙏❤️‍🩹
0 · Reply
MarketPulsee
MarketPulsee Jul. 19 at 3:14 PM
12 Dividend Stocks For Beginners | Long-Term Income Watchlist Building wealth isn’t only about growth — consistent dividend income can also play an important role. Here are 12 established dividend stocks to watch: $O Monthly dividend REIT focused on income $WMT Retail giant with consistent growth $MCD Global restaurant franchise leader $ABBV Healthcare company with strong dividend profile The best dividend stocks are not just high yield — they are companies that can continue growing and rewarding shareholders. Which dividend stocks do you own? Not financial advice. Always do your own research.
0 · Reply
opt_guru101
opt_guru101 Jul. 17 at 8:08 PM
$ABBV sub 250 next week...
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 17 at 7:25 PM
$SLS $ABBV $XBI " I strongly believe Gps will reach the study primary endpoint " - Dr. Tsirigotis treats more Phase 3 patients than any other doctor. 60th Event Dec 8th 2024 - IDMC Unblinded Actual MOS and IR Data from the Interim Analysis -- the SHARE PRICE LAUNCHED. 72nd Event - Dec 26th 2025 - the Share PRICE LAUNCHED 388 Days for 12 Events - 31 days Per Event 78th Event - May 11 2026 THE SHARE PRICE LAUNCHED AGAIN 136 Days for 6 Events - 1 Event Per 22 Days ... ITS BEEN 67 Days Since the the 78th ... - 80 Events are NOW IMMINENT and the CEO Just Told US ....
0 · Reply
GorillaTrades
GorillaTrades Jul. 17 at 7:11 PM
Top 3 #momentum #stocks In The GorillaTrades #portfolio This Week: Terreno Realty $TRNO +7.5%, Otter Tail $OTTR +4%, and AbbVie $ABBV +3.9%
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 17 at 7:01 PM
$SLS While we are Seeing Near Miraculous Extended Survival in the SLS Phase 3 AML Remission Maintenance Trial, Aza+VEN - Best Available Treatment (BAT) for the CONTROL ARM Patients - recently FAILED 3 Large Phase 3 AML Trials conducted by $ABBV BAT FAILED ... and Gps has proven successful in preventing relapse and extending survival, 2x 3x 4x in all Prior Trials - including 2 Phase 2 Trials for AML Remission Maintenance.
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 17 at 6:55 PM
$SLS Just ReChecking, do all you Short Scumbag Liars KNOW, Aza+VEN - Best Available Treatment (BAT) for the SLS REGAL Phase 3 CONTROL ARM Patients - recently FAILED 3 Large Phase 3 AML Trials conducted by $ABBV ? Including Failing the VIALE-M and VIALE-T Phase 3 trials for AML Remission Maintenance.??? Aza+VEN BAT for control arm Patients - also KILLED 23% of the VIALE-A Patients --- YES --- BAT for REGAL Control Patients actually Killed Nearly a quarter of the VIALE-A Patients. BAT for the SLS Control Arm Patients recently Failed 3 Large Phase 3 Trials Conducted by $ABBV ... Short Market Manipulation is offering the Investment Opportunity of Our Lifetimes. P3 Results worth 27X the Current Rigged Market Cap are Now IMMINENT. $XBI
2 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 17 at 5:05 PM
$SLS $ABBV $XBI Very Likely SLS Share Holders will be Seeing a 10x Plus ROI - Next Week. 10x and the Share Price will continue to climbing based on the True value of Gps an Immunotherapy that will Revolutionize AML Remission Maintenance. Note: there are 100,000+ US/Eu/J Acute Myeloid Leukemia Patients CURRENTLY in Remission who'll Immediately benefit from Gps -right out of the Gate Upon Approval - this year. - AML Patients - live in Fear, Each Day worried about this deadly disease returning. NO MORE. NO MORE. ABVX is a great example of the Power of Registratinal Phase 3 Results and the Impact on a small bio Share Price. b hodlin'
0 · Reply
DidYouReadThis
DidYouReadThis Jul. 17 at 4:04 PM
$ABBV $RHHBY $MRK $AZN
0 · Reply